Chronic Hepatitis C
Thymosin-alpha 1 improves interferon-alpha's efficacy against hepatitis C virus
Published in Hepatitis Weekly, March 15th, 2004
According to a study from Italy, "in this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha(2b) (3 million units three times a week) plus thymosin-alpha l (900 microgram/m2 body surface area) and 19 received interferon-alpha(2b) alone at the same dose. Patients were treated for 6 months and followed up for another 6 months."
"Biochemical (alanine aminotransferase values) and virological...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-03-15)
More Articles from Hepatitis Weekly
- Hematology
Renal function should dictate ribavirin dose in patients with hepatitis C - Oncology
Prechemotherapy HBV DNA marks viral reactivation risk in breast cancer patients - Chronic Hepatitis C
Extrahepatic manifestations abound where hepatic B cell expansion occurs - Hepatology
High leptin levels associate with fibrosis severity in chronic hepatitis C - Viral Genomics and Genetics
Adefovir therapy reduces hepatitis B virus load without generating mutants - Adverse Drug Effects
Ciprofloxacin intake generates a case of liver failure - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
